Patents by Inventor Elin Gunneriusson
Elin Gunneriusson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139352Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: March 8, 2023Publication date: May 2, 2024Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Patent number: 11633507Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: December 10, 2020Date of Patent: April 25, 2023Assignees: GENERAL ELECTRIC COMPANY, AFFIBODY ABInventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Patent number: 11505576Abstract: The disclosure provides a population of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence Xsc1AELDXsc2Xsc3GVG AXXIKXIXsc4XA XXVEXVQXXK QXILAX. The disclosure also provides methods for selecting and identifying polypeptides from the population, as well as such polypeptides themselves.Type: GrantFiled: March 12, 2019Date of Patent: November 22, 2022Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Sophia Hober, Sarah Lindbo
-
Publication number: 20210401930Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: ApplicationFiled: September 20, 2021Publication date: December 30, 2021Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 11155596Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.Type: GrantFiled: October 28, 2016Date of Patent: October 26, 2021Assignee: AFFIBODY ABInventors: Elisabet Wahlberg, Elin Gunneriusson
-
Patent number: 11123401Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: GrantFiled: December 20, 2018Date of Patent: September 21, 2021Assignee: IPC Research, LLCInventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Publication number: 20210170057Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: December 10, 2020Publication date: June 10, 2021Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Publication number: 20210047372Abstract: The disclosure provides a population of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence Xsc1AELDXsc2Xsc3GVG AXXIKXIXsc4XA XXVEXVQXXK QXILAX. The disclosure also provides methods for selecting and identifying polypeptides from the population, as well as such polypeptides themselves.Type: ApplicationFiled: March 12, 2019Publication date: February 18, 2021Inventors: Caroline Ekblad, Elin Gunneriusson, Sophia Hober, Sarah Lindbo
-
Patent number: 10894097Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: September 27, 2018Date of Patent: January 19, 2021Assignees: GENERAL ELECTRIC COMPANY, AFFIBODY ABInventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Publication number: 20200199197Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29 (SEQ ID NO:1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: January 15, 2020Publication date: June 25, 2020Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Patent number: 10669314Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-6, and provides an IL-6 binding polypeptide comprising the sequence EEX3X4AWX7EIH X11 LPNLX16X17X18QX20 X21AFIX25X26LX28X29. The present disclosure also relates to the use of such an IL-6 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.Type: GrantFiled: June 15, 2015Date of Patent: June 2, 2020Assignee: AFFIBODY ABInventors: Fredrik Frejd, Elin Gunneriusson, Ingmarie Höidén-Guthenberg, Per-Ake Nygren, Susanne Klint, Feifan Yu
-
Patent number: 10562955Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: December 14, 2017Date of Patent: February 18, 2020Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20190284241Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: April 8, 2019Publication date: September 19, 2019Inventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Publication number: 20190262481Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: September 27, 2018Publication date: August 29, 2019Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Patent number: 10323066Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: September 17, 2015Date of Patent: June 18, 2019Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Publication number: 20190167760Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: ApplicationFiled: December 20, 2018Publication date: June 6, 2019Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 10208128Abstract: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.Type: GrantFiled: October 27, 2010Date of Patent: February 19, 2019Assignee: AFFIBODY ABInventors: Fredrik Frejd, Elin Gunneriusson, Nina Kronqvist, John Löfblom, Stefan Ståhl
-
Patent number: 10206975Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: GrantFiled: September 29, 2017Date of Patent: February 19, 2019Assignee: Swedish Orphan Biovitrum AB (PUBL)Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 10159760Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: March 29, 2016Date of Patent: December 25, 2018Assignee: General Electric CompanyInventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
-
Publication number: 20180312565Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.Type: ApplicationFiled: October 28, 2016Publication date: November 1, 2018Inventors: Elisabet Wahlberg, Elin Gunneriusson